Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Additional screening criteria check may apply for qualification:~* Male and female Japanese patients, 40 years to 85 years at the time written informed consent is obtained.~* Patients who have been diagnosed with osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology (ACR) criteria.~* Patients with an evaluated joint (knee or hip) with a K-L (Kellgren-Lawrence) score of ≥2 based on the X-ray test performed.~* Moderate to severe pain in the evaluated joint, defined as a WOMAC pain score of ≥4 (mean of the 5 items), on the WOMAC assessments.~* Patients who satisfy both 1) and 2) below.~  1. Inadequate OA pain relief from at least 1 oral NSAID.~ 2. Intolerance to or inadequate OA pain relief from at least 1 opioid (including combination drugs), or unwillingness to take opioid therapy.~* Patients who agree to not change their current lifestyle (daily living activities and exercise) throughout the study.~* Patients who are able to complete post-operative follow-up for any joint replacement surgery that is performed during the study.~* Body mass index at screening ≤39.~* Patient who are able to understand and answer endpoint questions used in the study.~Exclusion Criteria:~Additional screening criteria check may apply for qualification:~* Presence of symptoms of carpal tunnel syndrome within 6 months before screening.~* Patients who cannot undergo MRI.~* Trauma to the index joint within 3 months prior to screening.~* Presence or history of inflammatory joint diseases other than OA, Paget's disease of the spine, pelvis or femur, multiple sclerosis, fibromyalgia, vertebral tumors or infections, or renal osteodystrophy.~* Presence or history, confirmed by imaging, of arthropathy, neuropathic joint arthropathy, hip dislocation, knee dislocation, extensive subchondral cyst, marked bone destruction or bone loss, or pathologic fractures.~* Autonomic neuropathy diagnosed in the assessment of autonomic nerve symptoms performed at screening, or baseline.~* Presence or history of orthostatic hypotension at the orthostatic hypotension assessments performed at screening, prerandomization, or baseline.~* Presence or history of autonomic neuropathy, diabetic neuropathy, or other peripheral neuropathy such as reflex sympathetic dystrophy at screening.~* Presence or history of chronic familial dysautonomia.~* Intolerance to naproxen.~* Systemic (excluding topical, intranasal, ophthalmic, and inhaled formulations) corticosteroids within 4 weeks prior to screening.~* Intra-articular corticosteroids in the evaluated joint within 12 weeks prior to screening, or in any other joint within 4 weeks prior to screening.~* Received an intra-articular injection of hyaluronic acid in any joint within the period specified for each medicine prior to screening.~* Resting heart rate of \<50 bpm or \>100 bpm at screening, or baseline.~* Presence or history of 2nd or 3rd degree heart block, 1st degree heart block with abnormal QRS, or bifascicular block by ECG assessment at screening.~* Non-compliance with the Numerical rating scale (NRS) recording (average pain on walking in the evaluated joint over 1 day) during the pre-treatment observation period.~* Women who are pregnant, breast-feeding, or may be pregnant.~* Use of an anti-Nerve growth factor (anti-NGF) antibody in the past, or apparent hypersensitivity or intolerance to anti-NGF antibodies.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MT-5547 dosing regimen 1 (Type: EXPERIMENTAL): MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
- MT-5547 dosing regimen 2 (Type: EXPERIMENTAL): MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
- MT-5547-matching placebo (Type: PLACEBO_COMPARATOR): MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).